Last reviewed · How we verify
Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine
Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine is a Biologic drug developed by U.S. Army Medical Research and Development Command. It is currently in Phase 1 development.
At a glance
| Generic name | Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine |
|---|---|
| Sponsor | U.S. Army Medical Research and Development Command |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Irritability
- Drowsiness
- Pain
- Redness
- Crying
- Somnolence
- Loss of appetite
- Injection Site Pain
- Swelling
- Pyrexia
- Injection Site Erythema
- Fever
Key clinical trials
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants (PHASE2)
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US (PHASE3)
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (PHASE3)
- Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (PHASE3)
- Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children (NA)
- A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) (PHASE3)
- Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine CI brief — competitive landscape report
- Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine updates RSS · CI watch RSS
- U.S. Army Medical Research and Development Command portfolio CI
Frequently asked questions about Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine
What is Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine?
Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine is a Biologic drug developed by U.S. Army Medical Research and Development Command.
Who makes Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine?
Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine is developed by U.S. Army Medical Research and Development Command (see full U.S. Army Medical Research and Development Command pipeline at /company/u-s-army-medical-research-and-development-command).
What development phase is Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine in?
Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine is in Phase 1.
What are the side effects of Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine?
Common side effects of Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine include Irritability, Drowsiness, Pain, Redness, Crying, Somnolence.